A Trial to Compare Ibrutinib Versus Lenalidomide in Combination With MRE-chemotherapy for Adult Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL)
This is a open-label，multicenter, randomised, three-arm, phase II efficacy and safety study of ibrutinib in combination with MRE(methotrexate,rituximab,etoposide)-chemotherapy versus lenalidomide in combination with MRE-chemotherapy given to adult patients who have recurrent/refractory primary central nervous system lymphoma (PCNSL)
Recurrent/RefractoryPrimary Central Nervous System Lymphoma (PCNSL)
DRUG: Ibrutinib|DRUG: Lenalidomide|DRUG: Methotrexate|DRUG: Rituximab|DRUG: Etoposide|DRUG: PEGylated recombinant human granulocyte colony
Progression-free survival (PFS), From date of randomization until recurrence/disease progression, unacceptable toxicity, death or discontinuation for any other reason, whichever comes first assessed up to 2 yrs, assessed up to 2 yrs
Objective response rate (ORR), To determine efficacy, assessed up to 2 yrs|Overall survival (OS), To determine efficacy, assessed up to 2 yrs|Number of patients with adverse events, Number of participants with treatment- and non-treatment related adverse events as assessed by CTCAE, assessed up to 2 yrs
This is a open-label，multicenter, randomised, three-arm, phase II efficacy and safety study of ibrutinib in combination with MRE(methotrexate,rituximab,etoposide)-chemotherapy versus lenalidomide in combination with MRE-chemotherapy given to adult patients who have recurrent/refractory primary central nervous system lymphoma (PCNSL)